Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis | Zendy

Justin Seroy | Zendy; Shellee A. Grim | Zendy; Gail Reid | Zendy; Trevor Wellington | Zendy; Nina M. Clark | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis

Author(s) -

Justin Seroy,

Shellee A. Grim,

Gail Reid,

Trevor Wellington,

Nina M. Clark

Publication year - 2016

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkw178

Subject(s) - fosfomycin , medicine , enterococcus faecalis , antibiotics , urinary system , pseudomonas aeruginosa , antimicrobial , dosing , incidence (geometry) , enterococcus , intensive care medicine , microbiology and biotechnology , bacteria , biology , staphylococcus aureus , genetics , physics , optics

Limited options for treating MDR organisms have led clinicians to turn to older antimicrobial agents that may display activity against such infections. One such agent is fosfomycin, an oral drug with activity against a variety of Gram-positive and -negative bacteria, but only approved for use in the USA for urinary tract infection (UTI) due to Escherichia coli and Enterococcus faecalis. The purpose of this study was to assess the efficacy of fosfomycin treatment of MDR UTI and identify predictors of outcome.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research